| 产品名称： | 41-2 PTA-226 |
|---|---|
| 商品货号： | TS212872 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Carcinoma |
| Applications： | Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135). The antibody may be useful for treating and diagnosing metastatic tumors. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with NS0 myeloma cells. |
| Comments： | Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135).
The antibody identifies SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135 kDa protein/CUB domain containing protein 1) PubMed: 12660814. Animals were immunized with metastatic human epidermoid carcinoma (HEp-3) cells by subtractive immunization.
Spleen cells were fused with NS0 myeloma cells.
The antibody may be useful for treating and diagnosing metastatic tumors.
A culture of 41-2 was deposited with the ATCC as PTA-226 in June of 1999. The cell line grown at ATCC is available as CRL-2695. The original patent deposit is available as PTA-226. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 x 10(6) cells/ml. Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 x 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG1 kappa |
| Name of Depositor： | Research Fndn. SUNY |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001 Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002 Hooper JD, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22: 1783-1794, 2003. PubMed: 12660814 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 41-2 PTA-226 |
|---|---|
| 商品货号： | TS212872 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Carcinoma |
| Applications： | Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135). The antibody may be useful for treating and diagnosing metastatic tumors. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with NS0 myeloma cells. |
| Comments： | Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135).
The antibody identifies SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135 kDa protein/CUB domain containing protein 1) PubMed: 12660814. Animals were immunized with metastatic human epidermoid carcinoma (HEp-3) cells by subtractive immunization.
Spleen cells were fused with NS0 myeloma cells.
The antibody may be useful for treating and diagnosing metastatic tumors.
A culture of 41-2 was deposited with the ATCC as PTA-226 in June of 1999. The cell line grown at ATCC is available as CRL-2695. The original patent deposit is available as PTA-226. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 x 10(6) cells/ml. Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 x 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG1 kappa |
| Name of Depositor： | Research Fndn. SUNY |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001 Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002 Hooper JD, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22: 1783-1794, 2003. PubMed: 12660814 |
